Core Viewpoint - The C3.ai class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, particularly in relation to CEO Thomas M. Siebel's health concerns, which ultimately led to a significant drop in stock price following disappointing financial results [1][4][5]. Group 1: Lawsuit Details - The lawsuit is titled Liggett v. C3.ai, Inc., No. 25-cv-07129, and is pending in the Northern District of California, representing purchasers or acquirers of C3.ai securities [1]. - The lawsuit claims that C3.ai's optimistic reports on growth and profitability were misleading and overly reliant on the health of its CEO [4]. - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal year 2026 and reduced its revenue guidance for the full fiscal year, attributing these issues to leadership reorganization and the CEO's health, resulting in a stock price drop of over 25% [5]. Group 2: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased C3.ai securities during the Class Period to seek appointment as lead plaintiff, representing the interests of the class [6]. - The lead plaintiff is typically the investor with the greatest financial interest in the case and can select a law firm to litigate the lawsuit [6]. Group 3: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years, indicating its prominence in the field [7].

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. and its executives for alleged violations of the Securities Exchange Act of 1934, claiming misleading information regarding the company's revenue outlook and CEO's health concerns [1][4]. Group 1: Lawsuit Details - The lawsuit is titled Liggett v. C3.ai, Inc., No. 25-cv-07129 (N.D. Cal.) and aims to represent purchasers or acquirers of C3.ai securities [1]. - Allegations include that C3.ai's executives created a false impression of reliable revenue projections while downplaying risks associated with CEO Thomas M. Siebel's health [4]. - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 FY 2026 and reduced its revenue guidance for the full fiscal year, attributing these issues to leadership reorganization and the CEO's health, leading to a stock price drop of over 25% [5]. Group 2: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased C3.ai securities during the Class Period to seek appointment as lead plaintiff [6]. - The lead plaintiff is typically the investor with the greatest financial interest and acts on behalf of all class members [6]. Group 3: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].

SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the C3.ai class action lawsuit – captioned Liggett v. C3.ai, Inc., No. 25-cv-07129 (N.D. Cal.) – seeks to represent purchasers or acquirers of C3.ai, Inc. (NYSE: AI) securities and charges C3.ai and certain of C3.ai’s executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the C3.ai class action lawsuit, please provi ...

If you suffered substantial losses and wish to serve as lead plaintiff of the C3.ai class action lawsuit, please provide your information here: https://www.rgrdlaw.com/cases-c3-ai-class-action-lawsuit-ai.html , /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the C3.ai class action lawsuit – captioned Liggett v. C3.ai, Inc., No. 25-cv-07129 (N.D. Cal.) – seeks to represent purchasers or acquirers of C3.ai, Inc. (NYSE: AI) securities and charges C3.ai and certain of C3.ai's executives with vio ...

SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the C3.ai class action lawsuit – captioned Liggett v. C3.ai, Inc., No. 25-cv-07129 (N.D. Cal.) – seeks to represent purchasers or acquirers of C3.ai, Inc. (NYSE: AI) securities and charges C3.ai as well as certain of C3.ai’s executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the C3.ai class action lawsuit, plea ...

Core Viewpoint - C3.ai, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding its revenue outlook and growth potential, particularly related to CEO Thomas M. Siebel's health issues [3][4]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased C3.ai securities between February 26, 2025, and August 8, 2025 [1]. - Investors have until October 21, 2025, to file a lead plaintiff motion [1]. Group 2: Allegations Against C3.ai - The lawsuit claims that C3.ai misled investors by presenting an overly optimistic revenue outlook while downplaying risks associated with the CEO's health [3]. - On August 8, 2025, C3.ai announced disappointing preliminary results for Q1 of fiscal year 2026 and lowered its full-year revenue guidance, attributing this to poor sales performance and CEO health concerns [4]. - Following this announcement, C3.ai's stock price dropped by more than 25% [4].

Core Viewpoint - The C3.ai class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, particularly in relation to CEO Thomas M. Siebel's health concerns, which ultimately led to a significant drop in stock price following disappointing financial results [1][4][5]. Group 1: Lawsuit Details - The lawsuit is titled Liggett v. C3.ai, Inc. and is filed in the Northern District of California, seeking to represent purchasers of C3.ai securities [1]. - The complaint claims that C3.ai's optimistic growth reports were misleading and overly reliant on the health of its CEO [4]. - Following the announcement of disappointing preliminary financial results for Q1 FY 2026 and a reduction in revenue guidance, C3.ai's stock price fell by more than 25% [5]. Group 2: Legal Process - Investors who suffered losses and wish to serve as lead plaintiff must file motions by October 21, 2025 [2][6]. - The lead plaintiff is typically the investor with the greatest financial interest and acts on behalf of all class members [6]. Group 3: Company Background - C3.ai operates as an enterprise artificial intelligence application software company [3]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [7].

Group 1 - The C3.ai class action lawsuit, titled Liggett v. C3.ai, Inc., seeks to represent purchasers of C3.ai securities and alleges violations of the Securities Exchange Act of 1934 by C3.ai and its executives [1] - The lawsuit claims that C3.ai misrepresented its revenue outlook and growth potential while downplaying risks associated with CEO Thomas M. Siebel's health [4] - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 FY 2026 and reduced its revenue guidance for the full fiscal year, leading to a stock price drop of over 25% [5] Group 2 - The lead plaintiff process allows any investor who purchased C3.ai securities during the Class Period to seek appointment as lead plaintiff, representing the interests of the class [6] - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]

Core Viewpoint - The C3.ai class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, particularly in relation to the health of CEO Thomas M. Siebel, leading to significant stock price declines following disappointing financial results [1][4][5]. Group 1: Lawsuit Details - The lawsuit, titled Liggett v. C3.ai, Inc., seeks to represent purchasers of C3.ai securities and claims violations of the Securities Exchange Act of 1934 [1][3]. - The lawsuit alleges that C3.ai's optimistic growth reports were misleading and overly reliant on the CEO's health, which was not disclosed adequately to investors [4][5]. - Following the announcement of disappointing preliminary financial results for Q1 FY 2026 and a reduction in revenue guidance, C3.ai's stock price fell by more than 25% [5]. Group 2: Legal Process - Investors who suffered losses can apply to be the lead plaintiff in the class action lawsuit, with the deadline for motions set for October 21, 2025 [2][6]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [6]. Group 3: Company Background - C3.ai operates as an enterprise artificial intelligence application software company [3].

Core Viewpoint - The C3.ai class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, particularly in relation to CEO Thomas M. Siebel's health concerns, leading to significant stock price declines following disappointing financial results [3][4]. Group 1: Lawsuit Details - The lawsuit, titled Liggett v. C3.ai, Inc., seeks to represent purchasers of C3.ai securities and claims violations of the Securities Exchange Act of 1934 [1][2]. - Allegations include creating a false impression of reliable revenue projections and minimizing risks associated with the CEO's health, which ultimately did not align with the company's actual performance [3]. Group 2: Financial Impact - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal year 2026 and reduced its revenue guidance for the full fiscal year, attributing these issues to leadership reorganization and the CEO's health [4]. - Following this announcement, C3.ai's stock price fell by more than 25% [4]. Group 3: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased C3.ai securities during the class period to seek appointment as lead plaintiff, representing the interests of the class [5]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been recognized for its significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [6].